My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.80 -0.84 (-1.54%)

Streaming Delayed Price Updated: 2:04 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

35 36 Next >

Is CRISPR Therapeutics a Buy? ↗

December 08, 2022

A strong cash position could offset some of the near-term risks that come with owning the biotech.

Via The Motley Fool

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

December 06, 2022

The company has already made plenty of investors happy.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

November 23, 2022

Via Benzinga

Why Shares of CRISPR Therapeutics Dropped 19.9% in October ↗

November 07, 2022

Several factors weighed on the gene-editing biotech stocks last month.

Via The Motley Fool

Where CRISPR Therapeutics Stands With Analysts ↗

November 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023 ↗

December 06, 2022

These top players are ripe for recovery -- and long-term growth.

Via The Motley Fool

3 Growth Stocks That Are Too Cheap to Ignore ↗

December 01, 2022

Overlooking these stocks in the current market could be a mistake.

Via The Motley Fool

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗

November 28, 2022

Here's how Ark Invest's top holdings have performed in 2022.

Via Investor's Business Daily

2 Stocks Near 52-Week Highs That Could Climb Higher ↗

November 28, 2022

This pair of stocks are bucking the trend and they could climb even higher.

Via The Motley Fool

Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead ↗

November 25, 2022

The ARK Invest founder might regret trimming her position in this biotech stock.

Via The Motley Fool

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

2 Growth Stocks That Could Double in 2023 ↗

November 17, 2022

Both are lagging the market this year.

Via The Motley Fool

Crispr Therapeutics Stock: Bull vs. Bear ↗

November 15, 2022

Crispr shares have fallen about 20% so far this year.

Via The Motley Fool

5 Top Stocks to Buy Before 2023 ↗

November 15, 2022

These stocks have what it takes to win over time.

Via The Motley Fool

Vertex Pharmaceuticals: Buy at the High? ↗

November 14, 2022

Vertex is submitting a potential blockbuster to regulators this month.

Via The Motley Fool

Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade ↗

November 12, 2022

These top stocks could be wise additions to a well-rounded investment portfolio.

Via The Motley Fool

3 Top Healthcare Stocks Defying the Bear Market ↗

November 10, 2022

These healthcare companies haven't been slowed by macroeconomic conditions.

Via The Motley Fool

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗

November 09, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

3 Healthcare Stocks That Could Go Parabolic ↗

November 09, 2022

These beaten-down stocks are ready for a rebound.

Via The Motley Fool

Got $1,000? 2 Smart Stocks to Consider Buying Right Now ↗

November 06, 2022

Don't overlook these major healthcare names on your next stock-buying spree.

Via The Motley Fool

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for November ↗

November 04, 2022

Catalysts lie ahead for these promising stocks.

Via The Motley Fool

What 8 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

November 02, 2022

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for CRISPR Therapeutics ↗

November 02, 2022

Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Better Buy: CRISPR Therapeutics vs. Bluebird Bio ↗

October 27, 2022

These two companies have performed almost equally poorly on the stock market in the past year.

Via The Motley Fool

2 Monster Stocks to Buy Without Any Hesitation ↗

October 26, 2022

These stocks are crushing the bear market.

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.